FLGT Quote, Financials, Valuation and Earnings

Delcath Systems, Inc. has a net margin of -8.12% compared to Fulgent Genetics, Inc.'s net margin of 4.04%. Fulgent Genetics, Inc.'s return on equity of -3.93% beat Delcath Systems, Inc.'s return on equity of 1.59%.

Fulgent Genetics, Inc. has a consensus price target of $33.67, signalling upside risk potential of 21.02%. On the other hand Delcath Systems, Inc. has an analysts' consensus of $22.33 which suggests that it could grow by 112.09%. Given that Delcath Systems, Inc. has higher upside potential than Fulgent Genetics, Inc., analysts believe Delcath Systems, Inc. is more attractive than Fulgent Genetics, Inc..

Fulgent Genetics, Inc. has a beta of 0.628, which suggesting that the stock is 37.151% less volatile than S&P 500. In comparison Delcath Systems, Inc. has a beta of 0.393, suggesting its less volatile than the S&P 500 by 60.664%.

Fulgent Genetics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Delcath Systems, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fulgent Genetics, Inc. pays -- of its earnings as a dividend. Delcath Systems, Inc. pays out -- of its earnings as a dividend.

Fulgent Genetics, Inc. quarterly revenues are $84.1M, which are larger than Delcath Systems, Inc. quarterly revenues of $20.6M. Fulgent Genetics, Inc.'s net income of -$6.8M is lower than Delcath Systems, Inc.'s net income of $830K. Notably, Fulgent Genetics, Inc.'s price-to-earnings ratio is -- while Delcath Systems, Inc.'s PE ratio is 1,210.34x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fulgent Genetics, Inc. is 2.71x versus 5.02x for Delcath Systems, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

EXACT Sciences Corp. has a net margin of -8.12% compared to Fulgent Genetics, Inc.'s net margin of -2.3%. Fulgent Genetics, Inc.'s return on equity of -3.93% beat EXACT Sciences Corp.'s return on equity of -38%.

Fulgent Genetics, Inc. has a consensus price target of $33.67, signalling upside risk potential of 21.02%. On the other hand EXACT Sciences Corp. has an analysts' consensus of $105.81 which suggests that it could grow by 3.47%. Given that Fulgent Genetics, Inc. has higher upside potential than EXACT Sciences Corp., analysts believe Fulgent Genetics, Inc. is more attractive than EXACT Sciences Corp..

Fulgent Genetics, Inc. has a beta of 0.628, which suggesting that the stock is 37.151% less volatile than S&P 500. In comparison EXACT Sciences Corp. has a beta of 1.404, suggesting its more volatile than the S&P 500 by 40.386%.

Fulgent Genetics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. EXACT Sciences Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fulgent Genetics, Inc. pays -- of its earnings as a dividend. EXACT Sciences Corp. pays out -- of its earnings as a dividend.

Fulgent Genetics, Inc. quarterly revenues are $84.1M, which are smaller than EXACT Sciences Corp. quarterly revenues of $850.7M. Fulgent Genetics, Inc.'s net income of -$6.8M is higher than EXACT Sciences Corp.'s net income of -$19.6M. Notably, Fulgent Genetics, Inc.'s price-to-earnings ratio is -- while EXACT Sciences Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fulgent Genetics, Inc. is 2.71x versus 6.22x for EXACT Sciences Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Illumina, Inc. has a net margin of -8.12% compared to Fulgent Genetics, Inc.'s net margin of 13.85%. Fulgent Genetics, Inc.'s return on equity of -3.93% beat Illumina, Inc.'s return on equity of 30.55%.

Fulgent Genetics, Inc. has a consensus price target of $33.67, signalling upside risk potential of 21.02%. On the other hand Illumina, Inc. has an analysts' consensus of $133.24 which suggests that it could fall by -11.34%. Given that Fulgent Genetics, Inc. has higher upside potential than Illumina, Inc., analysts believe Fulgent Genetics, Inc. is more attractive than Illumina, Inc..

Fulgent Genetics, Inc. has a beta of 0.628, which suggesting that the stock is 37.151% less volatile than S&P 500. In comparison Illumina, Inc. has a beta of 1.409, suggesting its more volatile than the S&P 500 by 40.855%.

Fulgent Genetics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Illumina, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fulgent Genetics, Inc. pays -- of its earnings as a dividend. Illumina, Inc. pays out -- of its earnings as a dividend.

Fulgent Genetics, Inc. quarterly revenues are $84.1M, which are smaller than Illumina, Inc. quarterly revenues of $1.1B. Fulgent Genetics, Inc.'s net income of -$6.8M is lower than Illumina, Inc.'s net income of $150M. Notably, Fulgent Genetics, Inc.'s price-to-earnings ratio is -- while Illumina, Inc.'s PE ratio is 33.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fulgent Genetics, Inc. is 2.71x versus 5.52x for Illumina, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Star Operating Cos., Inc. has a net margin of -8.12% compared to Fulgent Genetics, Inc.'s net margin of 14.56%. Fulgent Genetics, Inc.'s return on equity of -3.93% beat Star Operating Cos., Inc.'s return on equity of -3.67%.

Fulgent Genetics, Inc. has a consensus price target of $33.67, signalling upside risk potential of 21.02%. On the other hand Star Operating Cos., Inc. has an analysts' consensus of $12.00 which suggests that it could grow by 18.35%. Given that Fulgent Genetics, Inc. has higher upside potential than Star Operating Cos., Inc., analysts believe Fulgent Genetics, Inc. is more attractive than Star Operating Cos., Inc..

Fulgent Genetics, Inc. has a beta of 0.628, which suggesting that the stock is 37.151% less volatile than S&P 500. In comparison Star Operating Cos., Inc. has a beta of 2.711, suggesting its more volatile than the S&P 500 by 171.052%.

Fulgent Genetics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Star Operating Cos., Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fulgent Genetics, Inc. pays -- of its earnings as a dividend. Star Operating Cos., Inc. pays out 19.54% of its earnings as a dividend. Star Operating Cos., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Fulgent Genetics, Inc. quarterly revenues are $84.1M, which are larger than Star Operating Cos., Inc. quarterly revenues of $23.7M. Fulgent Genetics, Inc.'s net income of -$6.8M is lower than Star Operating Cos., Inc.'s net income of $3.5M. Notably, Fulgent Genetics, Inc.'s price-to-earnings ratio is -- while Star Operating Cos., Inc.'s PE ratio is 0.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fulgent Genetics, Inc. is 2.71x versus 0.48x for Star Operating Cos., Inc.. Usually stocks with elevated PS ratios are considered overvalued.